Nexalin Technology’s Leadership change follows Carolyn Shelton’s departure as senior vice president of Quality, Regulatory, and Clinical Affairs and includes a 2026 Bonus of $20,000. The separation agreement also accelerates unvested option vesting and extends benefits, while requiring releases and confidentiality provisions that define the departure terms for investors.

Key Highlights

  • Carolyn Shelton left Nexalin Technology on August 28, 2026, from her senior vice president role.
  • Health insurance premium subsidies continue through September 30, 2026.
  • The agreement accelerates unvested stock-option vesting and extends the exercise period for vested options.

Her separation agreement includes a 2026 bonus of $20,000, continued base salary and equity-related benefits.

Shelton Departure Terms Include Equity Benefits

The agreement accelerates vesting for Shelton’s unvested stock Options and gives her an extended period to exercise options that have already vested. Mark White, Nexalin Technology (NASDAQ: NXL)’s chief executive officer, signed the report on September 2, 2026.

Benefits Tied to Release and Ongoing Obligations

Shelton agreed to release claims in favor of Nexalin Technology as part of the separation terms. The agreement also contains confidentiality, non-disparagement and cooperation provisions.